1. An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway
    Jingyao Chen et al, 2021, Cancer Gene Therapy CrossRef
  2. Endometrial Carcinoma: Specific Targeted Pathways
    Nuria Eritja et al, 2017, Molecular Genetics of Endometrial Carcinoma CrossRef
  3. Fluorescent photoaffinity probes for mitotic protein kinase Aurora A
    Darja Lavogina et al, 2015, Bioorganic & Medicinal Chemistry Letters CrossRef
  4. DNA Methylation Module Network-Based Prognosis and Molecular Typing of Cancer
    Ze-Jia Cui et al, 2019, Genes CrossRef
  5. Efficient Gaussian sample specific network marker discovery and drug enrichment analysis validation
    Wenbin Liu et al, 2019, Computational Biology and Chemistry CrossRef
  6. Identification of Potential Crucial Genes Associated With the Pathogenesis and Prognosis of Endometrial Cancer
    Li Liu et al, 2019, Frontiers in Genetics CrossRef
  7. Endocervical trophoblast for interrogating the fetal genome and assessing pregnancy health at five weeks
    Leena Kadam et al, 2019, European Journal of Medical Genetics CrossRef
  8. Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies
    Kian-Huat Lim et al, 2021, European Journal of Cancer CrossRef
  9. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
    Stephanie Lheureux et al, 2018, Clinical Cancer Research CrossRef
  10. An update on the current pharmacotherapy for endometrial cancer
    Christopher de Haydu et al, 2016, Expert Opinion on Pharmacotherapy CrossRef
  11. TCGA dataset screening for genes implicated in endometrial cancer using RNA-seq profiling
    Xiaoli Fu et al, 2021, Cancer Genetics CrossRef
  12. A mathematical model of kinetochore-microtubule attachment regulated by Aurora A activity gradient describes chromosome oscillation and correction of erroneous attachments
    Manuel Alejandro CAMPOS MEDINA et al, 2021, Biomedical Research CrossRef
  13. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress
    Gerald S. Falchook et al, 2015, Seminars in Oncology CrossRef
  14. Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions
    Katherine N. Lynch et al, 2021, Cancers CrossRef
  15. In vivo serum enabled production of ultrafine nanotherapeutics for cancer treatment
    Qingxin Mu et al, 2020, Materials Today CrossRef
  16. Integrated pan‐cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance
    Noushin Miralaei et al, 2021, Cancer Medicine CrossRef
  17. The long-noncoding RNA SOCS2-AS1 suppresses endometrial cancer progression by regulating AURKA degradation
    Fangfang Jian et al, 2021, Cell Death & Disease CrossRef
  18. Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer
    Shikha Suman et al, 2017, Oncology Letters CrossRef
  19. Identification of key genes and pathways between type�I and type�II endometrial cancer using bioinformatics analysis
    Kai Zhang et al, 2019, Oncology Letters CrossRef
  20. GWAS for Meat and Carcass Traits Using Imputed Sequence Level Genotypes in Pooled F2-Designs in Pigs
    Clemens Falker-Gieske et al, 2019, G3 Genes|Genomes|Genetics CrossRef
  21. Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer
    Alice Bradfield et al, 2020, Methods and Protocols CrossRef
  22. San Huang Decoction Targets Aurora Kinase A to Inhibit Tumor Angiogenesis in Breast Cancer
    Yanlei Xu et al, 2020, Integrative Cancer Therapies CrossRef
  23. Chemoresistance in uterine cancer: Mechanisms of resistance and current therapies
    Abeer Arain et al, 2021, Overcoming Drug Resistance in Gynecologic Cancers CrossRef